Source comparison
IGF-1 LR3 vs HGH Injections: Research Application Comparison
Primary Mechanism Binds GH receptors → stimulates hepatic IGF-1 synthesis → systemic IGF-1 elevation Direct IGF-1 receptor activation. Bypasses liver synthesis and IGFBP regulation HGH for systemic studies; IGF-1 LR3 for receptor-level isolation Time to Peak E
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Binds GH receptors → stimulates hepatic IGF-1 synthesis → systemic IGF-1 elevation
- Direct IGF-1 receptor activation. Bypasses liver synthesis and IGFBP regulation
- HGH for systemic studies; IGF-1 LR3 for receptor-level isolation
- Time to Peak Effect
- 48–72 hours (serum IGF-1 peaks 12–24h, tissue activation lags)
- 4–6 hours (direct receptor activation within hours of injection)
- IGF-1 LR3 suits acute response studies; HGH suits chronic adaptation studies
- Half-Life
- 3–4 hours (serum), 12–18 hours (biological effect via IGF-1 synthesis)
- 20–24 hours (extended due to reduced IGFBP binding)
- IGF-1 LR3 allows less frequent dosing or precise timing alignment
- Tissue Selectivity
- Non-selective. Activates GH receptors in liver, muscle, adipose, bone, kidney
- Selective for IGF-1 receptors only. No GH receptor or insulin receptor cross-reactivity
- IGF-1 LR3 isolates IGF-1 signaling; HGH produces confounded multi-receptor effects
- Dosing Frequency
- Once daily (mimics physiological GH pulsatility)
- Once daily or every other day (extended half-life supports flexible schedules)
- Protocol design depends on measurement windows and receptor occupancy goals
- Metabolic Side Effects
- Diabetogenic at high doses (GH antagonizes insulin signaling)
- Hypoglycemic at high doses (IGF-1 mimics insulin via PI3K/Akt pathway)
- Opposite metabolic profiles. Glucose monitoring required for both